image credit: Unsplash

Anticancer Immunotherapy Response Predicted Using New Imaging Tool

Scientists at the University of Bath have developed a diagnostic tool that can predict whether a cancer patient is likely to respond to immune checkpoint inhibitor therapy. The method uses an imaging technique, iFRET, to directly assess interaction between programmed death ligand-1 (PD-L1) ligand with its receptor programmed death receptor-1 (PD-1), in patients’ tumor samples. The team hopes that the technique will allow clinicians to tailor treatments to individual patients and avoid treatment paths that are unlikely to be successful.

Read More on Genetic Engineering and Biotechnology News